Join the club for FREE to access the whole archive and other member benefits.

Isomorphic Labs on an expansion drive for its AI-enabled drug discovery


Key points from article :

Alphabet-owned Isomorphic Labs is ramping up its operations.

UK-registered group was spun out of its sister company DeepMind, Google’s AI unit, in November last year.

Isomorphic is currently in talks with major pharmaceutical companies and is expected to announce a deal in the next few months.

Demis Hassabis is chief executive of both DeepMind and Isomorphic Labs.

"... there was a real opportunity here to apply AI to reimagine drugs discovery,” said Colin Murdoch, chief business officer at DeepMind.

The goal is actually to build an underlying platform - not focused on a specific drug or disease.

Will then partner with pharma to get them out into the clinic.

AI-enabled drug discovery could lead to an additional 50 novel therapies over the next 10 years.

Isomorphic reported a £2.4mn loss for the 11 months to December 2021.

Plan is to build a generic platform then work with major pharma companies to take them to market

Mentioned in this article:

Click on resource name for more details.

Colin Murdoch

Chief Business Officer at DeepMind, Bootstrapping Isomorphic Labs

Isomorphic Labs

Discovering new drugs with AI-first approach